Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  2007-04-27

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BBRC.2007.02.129PMID 17350593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome.

  2006cited by this paper
• LIVER FAILURE AND LIVER DISEASE Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis

  2006cited by this paper
• COX‐2 induction in mice with experimental nutritional steatohepatitis: Role as pro‐inflammatory mediator

  2006cited by this paper
• Mitochondrial Dysfunction and Type 2 Diabetes

  2005cited by this paper
• Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

  2005cited by this paper
• Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat?

  2005cited by this paper
• NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis.

  2005cited by this paper
• Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease.

  2005cited by this paper
• Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice.

  2005cited by this paper
• Molecular mediators of hepatic steatosis and liver injury.

  2004cited by this paper
• NO-1886 inhibits size of adipocytes, suppresses plasma levels of tumor necrosis factor-alpha and free fatty acids, improves glucose metabolism in high-fat/high-sucrose-fed miniature pigs.

  2004cited by this paper
• Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice.

  2004cited by this paper
• Administration of the potent PPARα agonist, Wy‐14,643, reverses nutritional fibrosis and steatohepatitis in mice

  2004cited by this paper
• Non-alcoholic steatohepatitis in patients cared in metabolic units.

  2004cited by this paper
• PPARalpha in the pathogenesis of fatty liver disease.

  2004cited by this paper
• PPARα in the pathogenesis of fatty liver disease

  2004cited by this paper
• Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.

  2004cited by this paper
• Phyllanthus amarus has anti-inflammatory potential by inhibition of iNOS, COX-2, and cytokines via the NF-kappaB pathway.

  2003cited by this paper
• A Lipoprotein Lipase–Promoting Agent, NO-1886, Improves Glucose and Lipid Metabolism in High Fat, High Sucrose–Fed New Zealand White Rabbits

  2003cited by this paper
• Central role of PPARα‐dependent hepatic lipid turnover in dietary steatohepatitis in mice

  2003cited by this paper
• Non‐alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region?

  2003cited by this paper
• Phyllanthus amarus has anti-inflammatory potential by inhibition of iNOS, COX-2, and cytokines via the NF-κB pathway

  2003cited by this paper
• Serum Lipids, Lipoproteins and Apolipoproteins Levels in Patients With Nonalcoholic Steatohepatitis

  2003cited by this paper
• Hepatic ischemia reperfusion injury: Pathogenic mechanisms and basis for hepatoprotection

  2003cited by this paper
• Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

  2003cited by this paper
• PEROXISOMAL β-OXIDATION AND PEROXISOME PROLIFERATOR–ACTIVATED RECEPTOR α: An Adaptive Metabolic System

  2001cited by this paper
• Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system.

  2001cited by this paper
• Regulation of peroxisome proliferator activated receptor alpha-mediated pathways in alcohol fed cytochrome P450 2E1 deficient mice.

  2001cited by this paper
• The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet

  2000cited by this paper
• CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.

  2000cited by this paper
• Alcoholic liver disease: new insights in pathogenesis lead to new treatments.

  2000cited by this paper
• Nuclear Sterol Regulatory Element-binding Proteins Activate Genes Responsible for the Entire Program of Unsaturated Fatty Acid Biosynthesis in Transgenic Mouse Liver*

  1998cited by this paper
• The novel compound NO-1886 activates lipoprotein lipase in primary cultured adipose and skeletal muscle cells.

  1997cited by this paper
• Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells.

  1997cited by this paper
• Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a.

  1996cited by this paper
• Correction of Hypertriglyceridemia with Low High-Density Lipoprotein Cholesterol by the Novel Compound NO-1886, a Lipoprotein Lipase-Promoting Agent, in STZ-Induced Diabetic Rats

  1995cited by this paper
• The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis.

  1993cited by this paper

• Remnant cholesterol predicts long-term mortality of patients with metabolic dysfunction-associated fatty liver disease.

  2022cites this paper
• Ganoderic acid A attenuates high-fat-diet-induced liver injury in rats by regulating the lipid oxidation and liver inflammation

  2020cites this paper
• MDG-1, a Potential Regulator of PPARα and PPARγ, Ameliorates Dyslipidemia in Mice

  2017cites this paper
• Translational evaluation of cytochrome P450-derived epoxyeicosanoids in non-alcoholic steatohepatitis (NASH)

  2017cites this paper
• Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis.

  2016cites this paper
• Red bayberry extract prevents high-fat diet-induced metabolic disorders in C57BL/6 mice

  2015cites this paper
• Avaliação comparativa do efeito dos ácidos graxos oléico, palmítico e esteárico sobre biomarcadores do processo aterosclerótico

  2013cites this paper
• Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats

  2012cites this paper
• Hypolipidemic Activity of Eryngium carlinae on Streptozotocin-Induced Diabetic Rats

  2011cites this paper
• Lipoprotein Lipase as a Candidate Target for Cancer Prevention/Therapy

  2011influential citation
• Factors determining the progression of nonalcoholic fatty liver disease : the role of abnormal fatty acid and glucocorticoid metabolism

  2011cites this paper
• Heme oxygenase-1 protects against steatohepatitis in both cultured hepatocytes and mice.

  2010cites this paper
• NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1.

  2010cites this paper
• PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice.

  2009cites this paper
• The liver and the waistline: Fifty years of growth

  2009cites this paper
• The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.

  2008cites this paper
• The effect of cholesterol and orotic acid administration and methionin-cholin deficiency on liver DNA synthesis and lipid metabolism in rats

  2007cites this paper